A Long-term Follow-up Study to Assess Safety in Participants Who Received an Investigational T-Cell Receptor Engineered T-Cell (TCR-T) Product
TScan Therapeutics, Inc.
Summary
The purpose of this Long-Term Follow-Up (LTFU) study is to monitor participants who have previously received TSC-100 or TSC-101 TCR-T therapies in the TSCAN-001 study. Participants will be monitored for 15 years from the date of TCR-T cell therapy administration to assess long-term safety and efficacy.
Description
Participants will enroll in this LTFU study after completing the TSCAN-001 interventional trial. No additional study drug will be administered; however, participants may receive other cancer treatments as needed while being monitored for long-term safety. Enrollment will occur after completion of the TSCAN-001 study, and participants will be monitored for safety and efficacy over a 15 year period.
Eligibility
- Age range
- 18–110 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Participants who received a TCR-T cellular therapy in a clinical study sponsored by TScan Therapeutics. * Signed informed consent. Exclusion Criteria: * None
Interventions
- OtherObservational
Long Term Follow-Up for participants treated with TSC-100 or TSC-101 TCR-T products
Locations (2)
- City of HopeDuarte, California
- Mount SinaiNew York, New York